Please login to the form below
siponimod
This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.
Celgene hopes for second time lucky for ozanimod FDA filing
sales of $5bn once on the market, but this target could be harder to reach now, as Novartis has filed its rival SP1 targeting drug Mayzent(siponimod) in the meantime.
Latest news
-
Novartis: pipeline will generate 60 filings in three years
Those are headed by Mayzent (siponimod) – due to launch in the first quarter of 2019 – which it says is the “first and only drug proven to delay progression” in patients with
-
Novartis files for approval of MS drug in EU, US
Siponimod also seemed to have a meaningful benefit on patients’ cognitive processing speed in the study. ... Siponimod has an opportunity to tap into a niche not fully addressed by rival therapies.
-
Novartis drug works in secondary progressive MS
Orally-active siponimod reduces risk of disability progression. . A follow-up to Novartis' multiple sclerosis therapy Gilenya has been shown to work in a tough-to-treat form of multiple sclerosis ... MS). The new drug candidate - called siponimod
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow
-
Tackling a formidable foe
Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Competitive salary and benefits
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Cello Health
Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
